Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial

King, Madeleine T; Link, Emma K; Whelan, Tim J; Olivotto, Ivo A; Kunkler, Ian; Westenberg, Antonia Helen; Gruber, Guenther; Schofield, Penny; Chua, Boon H; Chua, Boon H; Phillips, Claire; Bryant, Guy; Westenberg, Helen; Purohit, Om Pra-Kesh; Ahern, Verity; Graham, Peter; Akra, Mohamed; McArdle, Orla; O'Brien, Peter; Ludbrook, Jane; Harvey, Jennifer; Maduro, John H; Gabelle-Flandin, Isabelle; Kirkove, Carine; Bedi, Carolyn; Martin, Joseph; Vu, Tony; Muanza, Theirry; Neal, Anthony; Courdi, Adel; Thariat, Juliette; Rakovitch, Eileen; Daniels, Laurien; van Hezewijk, Marjan; Cwajna, Wlasyslawa; Roelstraete, Adelheid; van Baardwijk, Angela; Russel, Nicola; Koch, Anne; Croke, Jennifer; Locke, Imogen; Jeal, Peter; Walker, Quenten; Thuraisingham, Kandeepeepan; Chauduri, Anupam; Joseph, David; Taylor, Mandy; Vanderkam, Sabine; Woo, Tony; Tang, Johann; Yassa, Michael; Wai, Elaine; Hewitt, Susan; Mahmood, Shazia; Gilmore, Jennifer; Ofi, Bolante; Bahl, Amit; Vujovic, Olga; Yu, Edward; Le, Duc; Kong, Iwa; Nichol, Alan; Bijker, Nina; Delaney, Geoff; Feigen, Malcolm; Lim, Adeline; Chao, Michael; Latham, Margaret; Algurafi, Hafiz; Tausch, Christoph; Khoo, Eric; Leung, Sam; Taylor, Karen; Senthi, Sasha; Stevens, Andrea; Chaudhuri, Abhro; Cleator, Susan; Brunt, Adrian Murray; Babington, Scott; Christie, David; Zwahlen, Daniel; Schratzenstaller, Ulrich; Masson, Laurence; Storey, Nicola; Kumar, Eshwar; Sherwin, Liz; Weytjens, Reinhilde; Ravi, Sharma; Lawton, Patricia; Angell, Ruth; Round, Glenys; Allen, Angela; Thotathil, Ziad; Anthes, Margaret; Reuter, Christiane; Pettit, Laura; Pettit, Laura; Zissiadis, Yvonne; Elder, Christine; Verbeek-de Kanter, Antoinette; Lirette, Andree; Plasswilm, Ludwig; Spooner, David; Hoar, Fiona; Mohamed, Islam; Lossl, Kristina; Loo, Vivienne; Richetti, Antonella; Evans, Tamasin; Hennessy, Aisling; El-Mallah, Medhat; Skala, Marketa; Awad, Raef; Germain, Isabelle; Mitine, Carine; Van Parijs, Hilde; Churn, Mark; Walji, Nawaz; Francis, Michael; Stellamans, Karin; Gruber, Gunther; Ivaldi, Giovanni; Alhasso, Abdulla; Kenny, Lizbeth; Tiver, Ken; Griffin, Matthew; Lamoury, Gillian; Trovo, Marco; Algufarfi, Hafiz; Walji, Nawaz; Lah, Minjae; Christie, David; Alhasso, Abdulla; Carruthers, Scott; Papadatos, George; Paardekooper, Gabriel; Chaudhuri, Abhro; Persic, Mojca; Lavery, Bernadette

doi:10.1016/s1470-2045(20)30085-1

All Outputs (7)

Breast cancer radiation therapy - Authors' reply. (2020)
Journal Article
Brunt, A. M., Haviland, J. S., Wheatley, D. A., & Yarnold, J. R. (2020). Breast cancer radiation therapy - Authors' reply. The Lancet, 396(10262), 1559 - 1560. https://doi.org/10.1016/S0140-6736%2820%2932320-5

FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 5-year results (2020)
Journal Article
Brunt. (2020). FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 5-year results. Radiotherapy and Oncology, S346 - S347. https://doi.org/10.1016/S0167-8140%2821%2900632-0

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer (2020)
Report
Brunt, A. M., Haviland, J. S., Sydenham, M., Agrawal, R. K., Algurafi, H., Alhasso, A., …Yarnold, J. R. (2020). Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

PURPOSE: Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evaluated normal tissue effects (NTE) and disease outcom... Read More about Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.

Breast Cancer Management Guidelines During COVID-19 Pandemic (2020)
Journal Article
Gowda S, M., Katherine Kabeer, K., Jafferbhoy, S., Marla, S., Soumian, S., Misra, V., …Brunt, A. M. (2020). Breast Cancer Management Guidelines During COVID-19 Pandemic. Indian Journal of Surgery, 82, 251-258. https://doi.org/10.1007/s12262-020-02466-7

The coronavirus disease (COVID-19) pandemic in 2020 has brought about complex challenges in healthcare delivery. With the new rules of lockdown and social distancing and with resources diverted to the management of COVID-19, there are difficulties in... Read More about Breast Cancer Management Guidelines During COVID-19 Pandemic.

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial (2020)
Journal Article
Brunt, A. M., Haviland, J. S., Wheatley, D. A., Sydenham, M. A., Alhasso, A., Bloomfield, D. J., …Management Group, F. T. (2020). Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet, 395(10237), 1613 - 1626. https://doi.org/10.1016/S0140-6736%2820%2930932-6

BACKGROUND: We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after pri... Read More about Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.

International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic (2020)
Journal Article
Coles, C. E., Aristei, C., Bliss, J., Boersma, L., Brunt, A. M., Chatterjee, S., …Rivera, S. (2020). International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clinical Oncology, 32(5), 279-281. https://doi.org/10.1016/j.clon.2020.03.006

'No abstract'

Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial (2020)
Journal Article
King, M. T., Link, E. K., Whelan, T. J., Olivotto, I. A., Kunkler, I., Westenberg, A. H., …Lavery, B. (2020). Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. Lancet Oncology, 21(5), 685-698. https://doi.org/10.1016/s1470-2045%2820%2930085-1

Background BIG 3-07/TROG 07.01 is an international, multicentre, randomised, controlled, phase 3 trial evaluating tumour bed boost and hypofractionation in patients with non-low-risk ductal carcinoma in situ following breast-conserving surgery and w... Read More about Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.